ARTICLE | Distillery Therapeutics

Therapeutics: CC chemokine receptor 2 (CCR2; CD192)

January 22, 2015 8:00 AM UTC

Mouse studies suggest CCR2 antagonists could help treat traumatic brain injury (TBI). In a mouse model of TBI, peripherally derived CCR2-expressing macrophages accumulated in the hippocampus and their accumulation was associated with inflammatory gene expression. In the mouse model, subcutaneous injection of the CCR2 antagonist CCX872 decreased macrophage accumulation, reactive oxygen species generation and TBI-induced cognitive dysfunction compared with vehicle. Next steps could include testing CCR2 antagonists in additional models of brain injury.

ChemoCentryx Inc. has CCX872 in Phase I testing to treat pancreatic cancer. ...